Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration

Retina

Volumn 29, Issue 5, 2009, Pages 699-703

  Abrishami, Majid ^a   Zarei Ghanavati, Siamak ^a   Soroush, Dina ^b   Rouhbakhsh, Majid ^a   Jaafari, Mahmoud R ^b   Malaekeh Nikouei, Bizhan ^b,c  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; LIPOSOME; NANOPARTICLE; 1,2 DIPALMITOYL SN GLYCERO 3 THIOPHOSPHOCHOLINE; 1,2-DIPALMITOYL-SN-GLYCERO-3-THIOPHOSPHOCHOLINE; ANGIOGENESIS INHIBITOR; CHOLESTEROL; MONOCLONAL ANTIBODY; PHOSPHATIDYLCHOLINE; PHOSPHORYLCHOLINE; VASCULOTROPIN A;

ANIMAL EXPERIMENT; AQUEOUS HUMOR; ARTICLE; CLINICAL EVALUATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ANALYSIS; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE; IN VIVO STUDY; NANOENCAPSULATION; NONHUMAN; RABBIT; SOLUBILITY; VITREOUS BODY; ANIMAL; BIOAVAILABILITY; CHEMISTRY; DRUG ANTAGONISM; INJECTION; METABOLISM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; AQUEOUS HUMOR; BIOLOGICAL AVAILABILITY; CHOLESTEROL; DRUG DELIVERY SYSTEMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; INJECTIONS; LIPOSOMES; PHOSPHATIDYLCHOLINES; PHOSPHORYLCHOLINE; RABBITS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 66349109049     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181a2f42a     Document Type: Article

References (30)

1. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-870.
2. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovas-cular age-related macular degeneration. Retina 2006;26:495-511.
3. Tewari A, Dhalla MS, Apte RS. Intravitreal bevacizumab for treatment of choroidal neovascularization in pathologic myopia. Retina 2006;26:1093-1094.
4. Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006;142:1054-1056.
5. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999-1005.
6. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113:1695.e1-15.
7. Spandau U, Wickenhauser A, Rensch F, Jonas J. Intravitreal bevacizumab for branch retinal vein occlusion. Acta Ophthalmol Scand 2007;85:118-119.
8. Eckerd C, Nicolai U, Czank M, Schmidt D. Ocular tissue after intravitreous silicone oil injection. Histological and electron microscopy studies. Ophthalmologe 1993;90:250-257.
9. Gambrelle J, Kodjikian L, Abi-Ayad N, et al. Persistent unsealed sclerotomy after intravitreal injection of triamcinolone acetonide with a 30-gauge needle. J Fr Ophtalmol 2006;29:22.
10. Meisner D, Mezei M. Liposome ocular delivery systems. Adv Drug Deliver Rev 1995;16:75-93.
11. Kshirsagar NA. Drug delivery systems. Indian J Pharm 2000; 32:554-561.
12. Lasic DD. Stealth liposomes. In: Microencapsulation: Methods and Industrial Applications. Benita S, ed. Marcel Dekker Inc: New York; 1996:259-295.
13. Fishman PH, Peyman GA, Lesar T. Intravitreal liposome encapsulated gentamicin in a rabbit model. Invest Ophthalmol Vis Sci 1986;27:1103-1106.
14. Peyman GA, Khoobehi B, Tawakol M, et al. Intravitreal injection of liposome-encapsulated ganciclovir in a rabbit model. Retina 1987;7:227-229.
15. Rao VS, Peyman GA, Khoobehi B, Vangipuram S. Evaluation of liposome-encapsulated clindamycin in Staphylococcus aureus endophthalmitis. Int Ophthalmol 1989;13:181-185.
16. Fiscella R, Peyman GA, Fishman PH. Duration of therapeutic levels of intravitreally injected liposome-encapsulated clinda-mycin in the rabbit. Can J Ophthalmol 1987;22:307-309.
17. Alghadyan AA, Peyman GA, Khoobehi B, Milner S, Liu KR. Liposome-bound cyclosporine: clearance after intravitreal injection. Int Ophthalmol 1988;12:109-112.
18. Lajavardi L, Bochot A, Camelo S, et al. Down regulation of endotoxin-induced uveitis by intravitreal injection of vasoac-tive intestinal peptide encapsulated in liposomes. Invest Ophthalmol Vis Sci 2007;48:3230-3238.
19. Bochot A, Fattal E, Boutet V, et al. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invest Ophthalmol Vis Sci 2002;43:253-259.
20. Kirby C, Gregoriadis G. Dehydration-rehydration vesicles: a simple method for high yield drug entrapment in liposomes. Biotechnology 1984;2:979-984.
21. Mordenti J, Thomsen K, Licko V, et al. Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation. Toxicol Sci 1999;52:101-106.
22. Ebrahim S, Peyman GA, Lee PJ. Application of liposomes in ophthalmology. Surv Ophthalmol 2005;50:167-182.
23. Gaudana R, Jwala J, Boddu SHS, Mitra AK. Recent Perspectives in ocular drug delivery. Pharm Res 2008; DOI:10.1007/ s11095-008-9694-0.
24. Kohno S, Tomono K, Maesaki S. Drug delivery systems for infection: liposome-incorporating antimicrobial drugs. J Infect Chemother 1998;4:159-173.
25. Sahoo SK, Dilnawaz F, Krishnakumar S. Nanotechnology in ocular drug delivery. Drug Discov Today 2008;13:144-151.
26. Herrero-Vanrell R, Refojo MF. Biodegradable microspheres for vitreoretinal drug delivery. Adv Drug Deliv Rev 2001;52: 5-16.
27. Martinez-Sancho C, Herrero-Vanrell R, Negro S. Vitamin A palmitate and acyclovir biodegradable microspheres for intraocular sustained release. Int J Pharm 2006;326:100-106.
28. Myles ME, Neumann DM, Hill JM. Recent progress in ocular drug delivery for posterior segment disease: Emphasis on transscleral iontophoresis. Adv Drug Deliv Rev 2005;57: 2063-2079.
29. Barza M, Stuart M, Szoka F. Effect of size and lipid composition on the pharmacokinetics of intravitreal liposomes. Invest Ophthalmol Vis Sci 1987;28:893-900.
30. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114: 855-859.